aid: axsome-therapeutics url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/apis.yml name: Axsome Therapeutics type: Index kind: contract access: 3rd-Party position: Consuming image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/apis-json-logo.jpg description: >- Axsome Therapeutics (NASDAQ: AXSM) is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders. Headquartered at One World Trade Center, New York, Axsome markets three FDA-approved products — Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for the acute treatment of migraine — and is advancing a pipeline including AXS-05 for Alzheimer's disease agitation and smoking cessation, AXS-12 (reboxetine) for narcolepsy, and AXS-14 (esreboxetine) for fibromyalgia. Axsome operates a corporate website and product / HCP microsites but does not expose a public developer API surface; this profile catalogs corporate, product, regulatory, and investor touchpoints rather than programmatic interfaces. tags: - Biopharmaceuticals - Biotechnology - Pharmaceuticals - Healthcare - Life Sciences - Neuroscience - Central Nervous System - Depression - Migraine - Narcolepsy - Alzheimers Disease Agitation - Fibromyalgia - Smoking Cessation - Clinical Pipeline - FDA Approved created: '2026-05-23' modified: '2026-05-23' specificationVersion: '0.19' maintainers: - FN: Kin Lane email: kin@apievangelist.com common: - type: DomainSecurity url: security/axsome-therapeutics-domain-security.yml - type: Website url: https://www.axsome.com/ - type: About url: https://www.axsome.com/about/ - type: Products url: https://www.axsome.com/products/ - type: Pipeline url: https://www.axsome.com/pipeline/ - type: Science url: https://www.axsome.com/science/ - type: Publications url: https://www.axsome.com/publications/ - type: MedicalInformation url: https://www.axsome.com/medical-information-us/ - type: MedicalInformationCanada url: https://www.axsome.com/medical-information-canada/ - type: ExpandedAccessPolicy url: https://www.axsome.com/expanded-access-policy/ - type: Careers url: https://www.axsome.com/careers/ - type: Investors url: https://www.axsome.com/investors/ - type: NewsRoom url: https://www.axsome.com/news-events/ - type: RSS url: https://www.axsome.com/feed/ - type: ContactUs url: https://www.axsome.com/contact-us/ - type: PrivacyPolicy url: https://www.axsome.com/privacy-notice/ - type: TermsOfService url: https://www.axsome.com/terms-of-use/ - type: StateDisclosures url: https://www.axsome.com/state-disclosures/ - type: IntellectualProperty url: https://www.axsome.com/intellectual-property/ - type: ManagementTeam url: https://www.axsome.com/management-team/ - type: BoardOfDirectors url: https://www.axsome.com/board-of-directors/ - type: LinkedIn url: https://www.linkedin.com/company/axsome-therapeutics - type: StockSymbol url: https://www.nasdaq.com/market-activity/stocks/axsm - type: SECFilings url: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001579428&type=10-K - type: Vocabulary url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/vocabulary/axsome-therapeutics-vocabulary.yml - type: JSONLD url: https://raw.githubusercontent.com/api-evangelist/axsome-therapeutics/refs/heads/main/json-ld/axsome-therapeutics-context.jsonld - type: ProductsList data: - name: Auvelity genericName: Dextromethorphan and Bupropion indication: Major Depressive Disorder (MDD) in adults status: FDA Approved productSite: https://www.auvelity.com hcpSite: https://www.auvelityhcp.com notes: Approved by the FDA in August 2022; oral NMDA receptor antagonist and sigma-1 receptor agonist combined with a CYP2D6 inhibitor. - name: Sunosi genericName: Solriamfetol indication: Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) in adults status: FDA Approved productSite: https://www.sunosi.com hcpSite: https://www.sunosihcp.com notes: Dopamine and norepinephrine reuptake inhibitor (DNRI); also approved in Canada and the European Union (EMA SmPC). - name: Symbravo genericName: Meloxicam and Rizatriptan indication: Acute treatment of migraine with or without aura in adults status: FDA Approved productSite: https://www.symbravo.com hcpSite: https://www.symbravohcp.com notes: FDA approved January 2025; multi-mechanistic, oral fixed-dose combination of an NSAID (meloxicam) and a 5-HT1B/1D receptor agonist (rizatriptan). - type: PipelineList data: - name: AXS-05 components: Dextromethorphan and Bupropion indication: Agitation associated with dementia due to Alzheimer's disease; smoking cessation status: Approved for Alzheimer's disease agitation; in development for additional indications mechanism: NMDA receptor antagonist and sigma-1 receptor agonist (dextromethorphan); CYP2D6 inhibitor and DNRI (bupropion) - name: AXS-12 genericName: Reboxetine indication: Narcolepsy (cataplexy and excessive daytime sleepiness) status: Investigational; FDA Orphan Drug Designation for narcolepsy mechanism: Selective norepinephrine reuptake inhibitor (NRI) - name: AXS-14 genericName: Esreboxetine indication: Fibromyalgia status: Investigational mechanism: Selective norepinephrine reuptake inhibitor (NRI), single enantiomer of reboxetine - type: ConditionsInFocus data: - name: Depression url: https://www.axsome.com/depression/ - name: Migraine url: https://www.axsome.com/migraine/ - name: Alzheimer's Disease Agitation url: https://www.axsome.com/alzheimers-disease-agitation/ - name: Excessive Daytime Sleepiness url: https://www.axsome.com/excessive-daytime-sleepiness/ - name: Narcolepsy url: https://www.axsome.com/narcolepsy/ - name: Fibromyalgia url: https://www.axsome.com/fibromyalgia/ - name: Smoking Cessation url: https://www.axsome.com/smoking-cessation/ - type: Address data: - street: One World Trade Center city: New York state: NY postalCode: '10007' country: USA - type: Features data: - name: CNS Therapeutic Focus description: Exclusive focus on central nervous system disorders spanning psychiatric, neurologic, and sleep-wake conditions. - name: Multi-Mechanistic Small Molecules description: Portfolio leverages combinations and single enantiomers acting on NMDA, sigma-1, monoamine reuptake, TAAR1, 5-HT, and GABA targets. - name: Commercial Stage with Three Approved Products description: Auvelity, Sunosi, and Symbravo are commercially marketed in the United States with sales force and patient support infrastructure. - name: Active Late-Stage Pipeline description: Pipeline candidates AXS-05, AXS-12, and AXS-14 address Alzheimer's disease agitation, narcolepsy, fibromyalgia, and smoking cessation. - name: Investor Disclosure description: Quarterly earnings, SEC filings (10-K, 10-Q, 8-K), webcasts, presentations, and analyst coverage published on the corporate site and EDGAR. - name: Medical Information Services description: U.S. and Canada medical-information request channels for healthcare professionals and patients. - type: UseCases data: - name: Healthcare Professional Prescribing description: HCP microsites for each marketed product provide prescribing information, dosing, safety, and access support. - name: Patient Access and Adherence description: Patient-facing brand sites with medication guides, copay assistance, and condition education. - name: Investor Relations description: Public disclosures, regulatory filings, and press releases for shareholders, analysts, and financial-data consumers. - name: Scientific Communication description: Publications, congress presentations, and medical-affairs touchpoints for the clinical and scientific community. - name: Clinical Trial Engagement description: Expanded Access Policy and trial-related communications for investigators and patients seeking access to investigational therapies. - type: Integrations data: - name: U.S. Food and Drug Administration (FDA) description: Regulatory submissions and approvals for NDA, sNDA, and post-marketing commitments covering Auvelity, Sunosi, Symbravo, and AXS-05. - name: European Medicines Agency (EMA) description: Sunosi (solriamfetol) maintains EMA authorization with SmPC and PIL published on the EMA website. - name: Health Canada description: Sunosi (solriamfetol) is approved in Canada with English and French product monographs and prescribing information. - name: NASDAQ / U.S. SEC description: Listed on NASDAQ as AXSM; periodic and current reports filed via EDGAR. - name: Specialty Pharmacy Networks description: U.S. distribution of branded CNS therapies through specialty and retail pharmacy partners. - name: Patient Support and Copay Programs description: Brand-specific patient support, copay assistance, and access services delivered via HCP and patient microsites. apis: []